Who Is Eligible for Mounjaro? | TODS Bangalore

Patient Education Series

Who Is Eligible for Mounjaro?

Mounjaro (Tirzepatide) is a powerful medication with a strong evidence base, but its safety and effectiveness depend on starting with the right patient, in the right clinical context, with appropriate monitoring in place.

📋 Clinical Criteria

🧬 Metabolic Health

🛡️ Safe Monitoring

📅 Book Your Consultation 💬 WhatsApp Us

27.5+

BMI starting
threshold (Indian)

18+

Years of age
requirement

Why This Matters

Understanding Right Fit & Clinical Context

One of the most important — and most underemphasised — aspects of GLP-1 therapy is that not everyone is a suitable candidate. This article is for anyone who has heard about Mounjaro and is wondering, "Is this something I could use?"

We will walk through the clinical eligibility criteria, the contraindications that make Mounjaro inappropriate, and what a proper eligibility assessment at TODS in Bangalore involves.

Being well-informed before your first appointment will help you have a more productive conversation with your physician, matching the right treatment to your specific metabolic profile.

📋

Quick Navigation

01 General Eligibility Criteria 02 BMI Thresholds: The South Asian Context 03 Comorbidities That Strengthen Candidacy 04 Medical Contraindications (Absolute) 05 Relative Contraindications and Caution Areas 06 Eligibility for Patients With Type 2 Diabetes 07 Eligibility for Patients With PCOS 08 What a Proper Assessment at TODS Involves 09 Who Is Not a Good Candidate? 10 Frequently Asked Questions

The Starting Point

General Criteria & South Asian BMI Thresholds

Mounjaro (Tirzepatide) is generally indicated for adults who meet specific clinical criteria related to body weight and metabolic health. The final eligibility decision is made through a comprehensive clinical assessment — not by self-checking a number on a scale.

Standard global BMI thresholds often use 30 as the cutoff for obesity. However, South Asian populations — including Indian patients — are known to develop cardiometabolic complications at lower BMI values. The South Asian Society for Atherosclerosis and Thrombosis (SASAT) and the Indian Council of Medical Research (ICMR) recommend lower, more appropriate thresholds.

⚖️

BMI ≥ 27.5

With at least one weight-related comorbidity (South Asian obesity threshold)

📈

BMI ≥ 32.5

General starting threshold even without an existing comorbidity

Waist circumference is an equally important marker. South Asian adults with a waist circumference above 90 cm (men) or 80 cm (women) carry significant central adiposity and cardiometabolic risk, regardless of overall BMI.

Medical Context

Comorbidities That Strengthen Candidacy

Patients with a BMI between 27.5 and 32.4 who have one or more of the following conditions are generally strong candidates for GLP-1 therapy. In each of these conditions, weight loss itself provides therapeutic benefit — and GLP-1 therapy's direct metabolic effects add additional value.

🩸

Metabolic Dysfunction

Type 2 diabetes, prediabetes, or established insulin resistance.

🫀

Cardiovascular Risk

Hypertension (high blood pressure), dyslipidaemia (elevated cholesterol), or established/high-risk cardiovascular disease.

🫁

Organ & Systemic Conditions

Obstructive sleep apnoea, NAFLD/NASH (fatty liver disease), or Polycystic ovary syndrome (PCOS) with insulin resistance.

Safety First

Medical Contraindications & Caution Areas

There are firm contraindications to Mounjaro use. These are not areas of clinical discretion — they are absolute exclusions. A thorough medical history review is a mandatory part of every TODS assessment before any GLP-1 medication is prescribed.

🚫

Absolute Contraindications

• Personal/family history of Medullary Thyroid Carcinoma (MTC)
• Multiple Endocrine Neoplasia type 2 (MEN2)
• Personal history of acute/chronic pancreatitis
• Known hypersensitivity to Tirzepatide
• Pregnancy (active or planned) or Breastfeeding
• Severe GI disease affecting gastric emptying (e.g., gastroparesis)

⚠️

Relative Caution Areas (Requires Close Monitoring)

• Significant renal impairment (eGFR < 30) or severe hepatic impairment
• History of gallbladder disease/gallstones
• Patients on complex insulin regimens (requires strict dose adjustment)
• Known eating disorders
• History of diabetic retinopathy

Special Populations

Eligibility for Patients With Type 2 Diabetes & PCOS

Certain metabolic conditions present highly favourable clinical scenarios for Mounjaro use, leveraging the drug's dual action on blood sugar and insulin sensitivity.

Type 2 Diabetes

Patients with type 2 diabetes are often excellent candidates, as Tirzepatide was originally developed as a diabetes medication. Note: Patients on insulin or sulfonylureas require expert dose adjustment to prevent hypoglycaemia, managed carefully at TODS.

Polycystic Ovary Syndrome (PCOS)

Strongly associated with insulin resistance and central obesity. Weight loss in PCOS patients often improves menstrual regularity, androgen levels, and fertility outcomes. We assess PCOS patients holistically considering both metabolic and reproductive goals.

The Process

What a Proper Assessment at TODS Involves

This assessment takes 45–60 minutes. It is the foundation of everything that follows — and it is what separates a properly supervised programme from a prescription issued without due diligence.

📏

Anthropometric Measurement

Comprehensive tracking including height, weight, BMI, and vital waist circumference measurements calibrated for the South Asian demographic.

🧪

Detailed Blood Work

HbA1c, fasting insulin, HOMA-IR, lipid panel, thyroid function (TSH), liver function (AST/ALT), kidney function, Vitamin D, and B12.

🩺

Medical & Family History

Thorough review of current medications, cardiovascular risk scoring, and blood pressure analysis to rule out any contraindications safely.

Honest Medicine

Who Is Not a Good Candidate?

To state this directly: not everyone who wants Mounjaro should take it. This is not about being exclusionary. It is about matching the right treatment to the right patient — which is the foundation of responsible, evidence-based medicine.

✖️

Inappropriate Candidates Include:

• Patients who do not meet BMI or metabolic eligibility criteria.
• Patients with firm medical contraindications.
• Patients who are unwilling to commit to the monitoring and lifestyle component of the programme.
• Patients who are primarily seeking cosmetic rather than medical outcomes.
• Patients who are pregnant or planning pregnancy.

Answers & Clarity

Frequently Asked Questions

Q: What BMI do I need for Mounjaro in India?

For South Asian patients, a BMI of 27.5 or above with a weight-related comorbidity, or 32.5 or above without, is the general starting threshold. Final eligibility is determined through a clinical assessment.

Q: Can I take Mounjaro if I have thyroid disease?

Mounjaro is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2. Other thyroid conditions require careful assessment. Discuss fully with your TODS physician.

Q: Is Mounjaro suitable for teenagers or patients under 18?

Mounjaro is currently approved for adults (18+) only. Use in paediatric or adolescent patients is not routinely recommended outside specialised clinical settings.

Q: Can I take Mounjaro if I am already on diabetes medication?

Possibly, but dose adjustments to your existing medications are usually required. This is managed carefully by your TODS physician to avoid hypoglycaemia.

Q: Is the assessment at TODS in person or online?

We recommend an in-person assessment for new patients, as physical measurements and examination are part of the evaluation. Video consultations may be available for follow-up in certain circumstances — please enquire.

Q: How do I check if I am eligible for Mounjaro at TODS?

Book a comprehensive assessment at todsindia.com. Our physicians will evaluate your full medical profile and discuss all relevant options with you.

⚕️

Medical Review Notice

Clinical Accuracy Verified

Reviewed by the TODS medical team for clinical accuracy. This article reflects current eligibility guidelines for Tirzepatide (Mounjaro) in India and is intended as patient education. Please consult a qualified physician for a personalised eligibility assessment.

Reviewed by: Dr. Tulip, MS, FMAS, FIAGES

Senior Bariatric & Metabolic Surgeon | Specialist in Obesity Medicine, Bariatric Surgery, Metabolic Health | TODS India, Bangalore

Serving Bangalore

Mounjaro Assessments Across Bangalore

🩺

Wondering if you are eligible for Mounjaro?

Get a definitive answer from our medical team. Book your comprehensive assessment at TODS today.